Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies. (2024)
Attributed to:
Autologous chimeric antigen receptor T cells targeting CCR9 for the treatment of T acute lymphoblastic leukaemia
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s41467-024-45854-3
PubMed Identifier: 38383515
Publication URI: http://europepmc.org/abstract/MED/38383515
Type: Journal Article/Review
Volume: 15
Parent Publication: Nature communications
Issue: 1
ISSN: 2041-1723